Tesamorelin vs Survodutide
Side-by-side comparison of key properties, dosing, and research.
Growth Hormone PeptidesFat Loss & Metabolic
TesamorelinGLP-1 / Weight Loss Agonists
Survodutide- Summary
- Tesamorelin is an FDA-approved synthetic GHRH analog specifically indicated for reduction of excess abdominal (visceral) fat in HIV patients with lipodystrophy. It is the only GHRH peptide with FDA approval for a fat-reduction indication and is studied off-label for metabolic syndrome and cognitive function.
- Survodutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Phase 2 trials demonstrated up to 18.7% body weight reduction at 46 weeks, among the highest reported for a dual agonist. It is being studied for obesity and MASH (metabolic dysfunction-associated steatohepatitis), where the glucagon component drives hepatic fat clearance.
- Half-Life
- ~26 minutes
- ~7 days
- Admin Route
- SubQ
- SubQ
- Research
- —
- —
- Typical Dose
- 2 mg
- 0.6 mg → 2.4 mg → 4.8 mg → 6 mg
- Frequency
- Once daily
- Once weekly
- Key Benefits
- FDA-approved for visceral fat reduction in HIV lipodystrophy
- Significant reduction in trunk/visceral fat (average 15–20% in trials)
- Improved triglyceride and lipid profiles
- Potential cognitive benefits and memory improvement
- Preserves lean mass while reducing fat
- Natural pulsatile GH stimulation
- Up to 18.7% body weight reduction at 46 weeks (Phase 2)
- Strong MASH activity — Phase 3 SYNCHRONIZE-NASH trials ongoing
- Reduces hepatic fat content via glucagon receptor-driven liver oxidation
- Once-weekly subcutaneous injection
- Greater weight loss potential than GLP-1 monotherapy
- Improvements in liver fibrosis markers in early data
- Side Effects
- Injection site reactions (redness, irritation)
- Arthralgia and joint pain
- Peripheral edema
- Carpal tunnel syndrome
- +2 more
- Nausea (most common during titration)
- Vomiting
- Diarrhea
- Decreased appetite
- +3 more
- Stacks With
- —
- —